2022 Program

The Biotech CEO Summits are unlike most other meetings CEOs attend. The Summits focus on the participating CEOs discussing issues of importance to them as leaders of companies they want to position for growth and success. The Summits are discussion based meetings led by subject matter experts. All participants are invited to, and indeed encouraged to join the discussions by asking questions and sharing their personal insights. The Summits are run under Chatham House Rules to encourage open and frank conversation. The media are not invited, and the sessions are not recorded, to provide an extra layer of privacy.

Monday, May 9

14:00

Registration

16:30

Icebreaker Activities: Coworth Activity Field

18:30

Opening Program & Introductions: The Barn

  • Sara Jane Demy, Founder and CEO, Demy-Colton
19:30

Fireside Chat: The Purposeful CEO: Fulfilling the Promise of Company Transformation

  • Introduction: Katja Stout, Managing Director, Scius Communications
  • Moderator: Stephanie Léouzon, Partner & Head, Torreya Europe
  • William “Bill” Enright, CEO, Vaccitech plc
20:15 Networking Dinner: The Barn

Tuesday, May 10

07:00

Private Breakfast: Garden Room

08:30

Summit Overview & Rules of Engagement: Oval Room

  • Sara Jane Demy, Founder & CEO, Demy-Colton
08:45

The Pulse of European Biotechnology: A Discussion
Do you think it is stronger than ever? Is there enough funding? Is the regulatory environment friendly? What challenges are impeding your growth?

  • Stephanie Léouzon, Partner & Head, Torreya Europe
  • Nooman Haque, Managing Director, Life Sciences & Healthcare, SVB UK
09:30

A Conversation about Fundraising in Good Times and Bad (VC/PE?)

First Covid-19 provided an unexpected boost to biotech and the broader markets, then the macro-economic fallout took the wind out of the bull market’s sails, and now another disruption

has sent investors scrambling. Biotech remains a cash-intensive business. How are you coping with the current challenges?

  • Joe Anderson, Partner, Crossover Strategy, Sofinnova Partners
  • Gabe Cavazos, Senior Managing Director, Investment Banking, SVB Securities
  • Antonin (Tony) de Fougerolles, CEO, Evox Therapeutics
  • Nicholas Moore, Managing Director, Healthcare Investment Banking, Stifel
10:30

NETWORKING BREAK

11:00

Venture Capital: More, Bigger European Funds, What Does it Mean?

Many European venture funds have raised record amounts. There are more investors and more cash but how do you get investors’ attention? Does demand still outstrip supply for capital and how does this affect you? What strategies can help you?

  • Karin Kleinhans, Partner, LSP
  • Stephanie Léouzon, Partner & Head, Torreya Europe
12:00

Making the Decision to Go Public:  All Signs Seem to Point to the US – Is This Right for You?

If you are tired of waiting for improved liquidity and access to capital on European exchanges (or a pan-European stock market in Europe), should you consider skipping your market and listing directly on US Nasdaq? Let’s discuss the options.

  • Renee Aguiar-Lucander, CEO, Calliditas Therapeutics AB
  • Gabe Cavazos, Senior Managing Director, Investment Banking, SVB Securities
  • Edwin Moses, Independent Director
  • Denise Scots-Knight, CEO, Mereo BioPharma
13:00

NETWORKING LUNCH: GARDEN ROOM

14:00

Institutional Investors: Expanding Your Network & Setting the Stage for Growth
Winning investors is about establishing access and trust. The first step is showing up. How can companies grow their network and achieve access through storytelling and intermediaries, estimating the time, staff and cost requirements?

  • Renee Aguiar-Lucander, CEO, Calliditas Therapeutics AB
  • Joe Anderson, Partner, Crossover Strategy, Sofinnova Partners
  • Sarah Gordon Wild, Managing Director, SGW Research Ltd.
  • Chris Maggos, Managing Director, BioConfidant Sàrl
  • Gretchen Schweitzer, Managing Director, Trophic Communications
15:00

Understanding US Investors: The Nuances Every Successful EU CEO Should Know

US investors have a different phenotype compared to many of their European counterparts. But the keys to navigating to the New World go beyond communication style and require thoughtful preparation and long-term commitment.

  • Sarah Gordon Wild, Non-Executive Director, Evox Therapeutics
  • Chris Maggos, Managing Director, BioConfidant Sàrl
  • Gretchen Schweitzer, Managing Director, Trophic Communications
16:00

NETWORKING BREAK

16:30

Biotech and The Beautiful Game: Leadership Learnings from Cambridge United Football Club

How underfunded Cambridge United changed its leadership and culture, punched above its weight and achieved promotion in a pandemic to the third tier of English football and pulled off one of the biggest sporting upsets in the history of the game.

  • Moderator:
    • Denise Scots-Knight, CEO, Mereo BioPharma Group
  • Panelists:
    • Graham Daniels, Charitable Trust Chair, Cambridge United Football Club

    • Shaun Grady, Chair, Cambridge United Football Club & SVP Business Development Operations, AstraZeneca

    • Ben Strang, Sporting Director, Cambridge United Football Club
17:30

Day 1 Wrap-Up

18:00

Biotech CEO Summit Europe Games & Reception: Rose Garden

19:30 TAKE A BREATHER
20:00 Dinner: Restaurant Coworth Park

Wednesday, May 11

07:00

Private Breakfast: Garden Room

07:55

Welcome Back: Oval Room

  • Sara Jane Demy, Founder & CEO, Demy-Colton
08:30

Market Access: Preparing for Commercial Success
Preparing for regulatory and marketing success starts earlier than many would expect. Establishing a target product profile early can determine a company’s success or failure.

  • Ted Haack, VP, Lattice Point Consulting
  • Paul Pay, Senior Advisor, Torreya
09:15

Valuation: Understanding the Perspective of Investors and Potential Partners

An insider’s view of the impact of different assumptions and how they affect valuation and licensing deal terms. What you can and cannot address with valuation.

  • Patrik Frei, Founder & CEO, Venture Valuation AG
  • Ted Haack, VP, Lattice Point Consulting
  • Chris Maggos, Managing Director, BioConfidant Sàrl
10:00

NETWORKING BREAK

10:15

Building a Life Science Leadership Team: The Last Two Years and Current Challenges

Team building is always a challenge for innovative companies seeking to deliver life-changing medicines. Finding the right people who not only fit your organization but enhance it — always a challenge — is more difficult in the current market. What strategies should you consider? How do you address diversity? What can you do to make your company more attractive than the competition?  In this post-pandemic environment, is a virtual work option part of the new normal?

  • Bianca Coulter, CEO, Coulter Partners
  • Edwin Moses, Independent Director
11:00

Fireside Chat: Getting Your Board Right to Accelerate Growth

Selecting board members to take your company to the next level. Competencies, networks, diversity, and engagement. Finding the recipe for a board that will suit your company.

  • Bianca Coulter, CEO, Coulter Partners
  • Edwin Moses, Independent Director
11:45

Building a New Communication Process, Finding THE Message and Designing and Executing a Communication Plan

Small management teams must consider their key targets (i.e., current and future investors, potential partners, the media, patient groups, the board, current and future employees, regulatory authorities and more) and the benefits of building a social media presence.

  • Chris Maggos, Managing Director, BioConfidant Sàrl
  • Gretchen Schweitzer, Managing Director, Trophic Communications
12:30

NETWORKING LUNCH: GARDEN ROOM

13:30

An Unguarded Conversation Among Friends

14:15

Wrap Up Biotech CEO Summit Europe – Sara Jane Demy

14:30

Closing Reception: Garden Room